Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Mr. Sunao Manabe D.V.M., Ph.D. | Group CEO & Executive Chairperson | 1.81M | -- | 1954 |
| Mr. Hiroyuki Okuzawa | President, COO & Representative Director | 1.22M | -- | 1962 |
| Mr. Takashi Fukuoka D.V.M., Ph.D. | Senior Managing Exec. Officer, Global Head of Corporate Strategy, Chief Strategy Officer & Director | 710.19k | -- | 1961 |
| Dr. Shoji Hirashima | Senior Managing Executive Officer, Head of Japan Business Unit & Representative Director | 798.97k | -- | 1961 |
| Mr. Koji Ogawa | Managing Ex. Officer, Head of Corporate Planning & Mgt. and CFO | -- | -- | -- |
| Tomohiro Kodama | General Manager of Finance & Accounting Department | -- | -- | -- |
| Hiroto Kashiwase | Executive Officer & Head of Technology Division | -- | -- | -- |
| Naoto Tsukaguchi | Gen. Counsel, Corp. Officer, Head of Global Legal & IP and VP of Leg. Aff. Dept. | -- | -- | -- |
| Matt Allegrucci | Head of Global Compliance & Risk Management and Chief Compliance Officer | -- | -- | -- |
| Kentaro Asakura | Vice President of Corporate Communications Department | -- | -- | -- |
Daiichi Sankyo Company, Limited
- Sector:
- Healthcare
- Industry: Drug Manufacturers - General
- Full Time Employees:
- 18,726
Description
Daiichi Sankyo Company, Limited manufactures and sells pharmaceutical products in Japan, North America, Europe, and internationally. The company offers Enhertu to treat patients with HER2 positive and low breast cancer, HER2 positive gastric or gastroesophageal junction adenocarcinoma, and HER2 positive solid tumors; Turalio, an oral small molecule that targets colony stimulating factor 1 receptor, KIT proto-oncogene receptor tyrosine kinase, and FMS-like tyrosine kinase 3 harboring an internal tandem duplication mutation; Vanflyta, a FLT3 inhibitor for the treatment of adult patients with acute myeloid leukemia; and Injectafer, a ferric carboxymaltose injection to treat iron deficiency. It also provides Liziana and Savaysa, direct factor Xa inhibitors; Minnebro, Olmetec, Olmetec Plus, Rezaltas, Sevikar, and Sevikar HCT antihypertensive agents; Nilemdo, an oral treatment which lowers cholesterol; Nustendi, a fixed-dose combination tablet of bempedoic acid and ezetimibe to reduce cholesterol; and Efient, an anti-platelet agent. In addition, the company offers Canalia and Tenelia for the treatment of type 2 diabetes mellitus; Emgalty and Reyvow to treat migraine attacks; Pralia for the treatment of osteoporosis/inhibitor of the progression of bone erosion associated with rheumatoid arthritis; Ranmark to treat bone complications caused by bone metastasis from tumors; Tarlige for treating neuropathic pain; Venofer for the treatment of iron deficiency anemia; and Vimpat, an anti-seizure medication. Further, it provides vaccines for COVID-19 infection, influenza infection, adsorbed cell culture-derived influenza (H5N1), measles/rubella infection, and mumps. The company has a development and sales collaboration with Merck & Co., Inc. and AstraZeneca UK Limited to develop anti-cancer drugs. Daiichi Sankyo Company, Limited was founded in 1899 and is headquartered in Tokyo, Japan.
Corporate Governance
Upcoming Events
January 31, 2025 at 4:00 AM UTC
Daiichi Sankyo Company, Limited Earnings Date
March 28, 2025 at 12:00 AM UTC
Ex-Dividend Date
Recent Events
December 1, 2011 at 12:00 AM UTC
Dividend Date